Despite all the changes, it seems likely that compounding pharmacies will continue to offer GLP-1 drugs, at least for the foreseeable future, says Brunner: Some patients will be able to maintain these therapies at a price point they can afford in a customized formulation. The Takeaway The FDA ordered compounding pharmacies to stop producing and selling copies of GLP-1 injectable drugs like Ozempic, Wegovy, Mounjaro, and Zepbound, as official shortages have ended
amycretin has no CV data Conclusion# Amycretin represents the most exciting pipeline asset in obesity medicine, with 24.3% weight loss in early trials suggesting it could substantially exceed every approved treatment
14,16,17 These integrated actions support glucose homeostasis and contribute to body weight reduction
GLP-1 receptor agonist use was not associated with a substantially increased risk of thyroid cancer over a mean follow-up of 3.9 years, Bjrn Pasternak, MD, PhD, associate professor and principal researcher in the division of pharmacoepidemiology, department of medicine at Karolinska Institutet in Sweden, and colleagues wrote
As these medications come in injectable form, they are administered as a once weekly injection under the skin (subcutaneously) in the belly, outer thighs, upper buttocks, or the back of the arms
